Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310963 | 1.00 | KMT2A (0.57) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL11286970 | 0.80 | TNKS2 (0.58) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL29258994 | 0.77 | KDM4E (0.74) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL31702781 | 0.75 | KDM4E (0.74) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL6124127 | 0.73 | KMT2A (0.52) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL13035690 | 0.73 | MEN1 (1.00) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL30073748 | 0.73 | MAPT (0.68) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL28837989 | 0.73 | MAPT (0.68) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL7859229 | 0.70 | GAA (0.65) | KMT2AMEN1GAAMAPTKDM4E | |
| SCHEMBL6124233 | 0.69 | TNKS2 (0.49) | KMT2AMEN1GAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398821-A1 | FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE | UNIV RUTGERS (US) | 2024-12-05 | — | — | US | disclosed |
| CN-118354770-A | Flavonoid derivatives having GABAA receptor activity and methods of use | 罗特格斯新泽西州立大学 | 2024-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398821-A1 | FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE | GABRB1, GABRB2, GABBR1 | KMT2A 1898/4885MEN1 4591/4885GAA 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.